UPDATE: SVB Leerink On Theseus Outperform Initiation: Firm Highlights Co.’s Lead Asset THE-630, Which ‘Covers All Known Major Classes Of KIT Activating & Resistance Mutations In GIST’; Notes EGFR Inhibitor Program As Additional Key Value Driver

by | Nov 1, 2021 | Uncategorized | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.